🦠
MicroDAO Whitepaper
  • MICRO: Funding the next generation of AMR Solutions: Antimicrobials, Diagnostics, and Vaccines
    • Executive Summary
    • The AMR Challenge
      • Understanding Antimicrobial Resistance
      • The Human Innovation Gap
      • Investments into AMR solutions
    • microDAO: A Community-Driven Solution to Tackle AMR
      • Vision and Mission
      • Operational Framework
      • Structure of microDAO
        • Core Team
        • Community Members
        • Token Holders
        • Working Groups
        • Service Providers
        • Partners
        • End users of solutions and funding offered by microDAO
    • DAO Way of Working
    • microDAO’s Flywheel for Impact and Revenue: Community Tools and Workflows
      • Evidence Generation & Decision Support Tools
      • R&D Acceleration Tools
    • microDAO Revenue Streams: Building Sustainable Impact
    • Fund Allocation Strategy for liquid funds available in the DAO treasury
      • Strategic Priority Areas
        • Early-Stage Research Development
        • Clinical Development Support
        • Equitable Access Programmes
        • Infrastructure and Tools
        • Operational Sustainability
    • Impact and Future Outlook
Powered by GitBook
On this page
  1. MICRO: Funding the next generation of AMR Solutions: Antimicrobials, Diagnostics, and Vaccines
  2. Fund Allocation Strategy for liquid funds available in the DAO treasury

Strategic Priority Areas

While there are five key strategic priority areas for microDAO's fund allocation, the DAO's fund allocation strategy remains flexible, allowing us to respond to emerging threats and opportunities while maintaining our core focus on AMR innovation and access. Regular review and adjustment of funding priorities ensures we maintain alignment with our mission while maximising impact across the AMR research and development pipeline.

PreviousFund Allocation Strategy for liquid funds available in the DAO treasuryNextEarly-Stage Research Development

Last updated 6 months ago